Medicare Bridge vs Compounded GLP-1: Which Actually Costs Less?

The Medicare GLP-1 Bridge offers a flat $50 monthly copay. At first glance, that undercuts every compounded option on the market. But the real cost comparison is more nuanced than the headline number suggests.

The $50 Copay: What It Includes

The Bridge copay covers one monthly supply (28- or 30-day fill) of an eligible GLP-1 medication. No deductible applies. The $50 is your total out-of-pocket — it doesn't count toward your Part D out-of-pocket maximum or deductible. Manufacturer coupons and discount programs cannot be applied on top of the Bridge copay.

This is a genuine $50/month, all-in. For brand Wegovy (which lists at approximately $1,349/month) or Zepbound (approximately $1,087/month), the savings are substantial.

12-Month Cost Comparison

When Compounded Wins

Despite the Bridge's lower price, compounded GLP-1s remain the better option for several patient groups:

Not on Medicare. The Bridge is exclusively for Medicare Part D beneficiaries. If you're under 65, on employer insurance, uninsured, or on Medicaid without Part D, the Bridge doesn't exist for you. Compounded remains the primary affordable pathway.

Need custom dosing. Brand pens come in fixed dose increments. Compounded medications allow titration in smaller steps — 0.25mg, 0.375mg, 0.5mg, 0.625mg — which can reduce side effects during escalation. Some patients stabilize at non-standard doses that brand products don't offer.

Already on a GLP-1 through Part D. If your Part D plan covers your GLP-1 for diabetes, sleep apnea, or MASH, you're ineligible for the Bridge even if you also want weight management benefits. And your Part D copay may be higher than compounded pricing.

Concerned about program discontinuation. The Bridge runs through December 31, 2027. The BALANCE Model (its intended successor) has been delayed indefinitely. Patients who build their treatment around the Bridge face a potential cliff in 18 months.

When the Bridge Wins

For eligible Medicare beneficiaries who can use standard brand doses, $50/month is unbeatable. It's less than half the cheapest compounded option. The medication is FDA-approved with established safety data. And the prior authorization, while cumbersome initially, is valid through the end of the program without renewal.

The Hybrid Approach

Some patients are considering a pragmatic middle ground: use the Bridge while it lasts, maintain a relationship with a 503A compounding pharmacy, and have a fallback plan for 2028. This hedges against both regulatory risk (compounding restrictions) and program risk (Bridge discontinuation).